Immunotherapy for pediatric brain tumors: Past and present

Jessica B. Foster; Peter J. Madsen; Meenakshi Hegde; Nabil Ahmed; Kristina A. Cole; John M. Maris; Adam C. Resnick; Phillip B. Storm; Angela J. Waanders

doi:10.1093/neuonc/noz077

Immunotherapy for pediatric brain tumors: Past and present

Jessica B. Foster, Peter J. Madsen, Meenakshi Hegde, Nabil Ahmed, Kristina A. Cole, John M. Maris, Adam C. Resnick, Phillip B. Storm, Angela J. Waanders^*

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

The field of cancer immunotherapy has progressed at an accelerated rate over the past decade. Pediatric brain tumors thus far have presented a formidable challenge for immunotherapy development, given their typically low mutational burden, location behind the blood-brain barrier in a unique tumor microenvironment, and intratumoral heterogeneity. Despite these challenges, recent developments in the field have resulted in exciting preclinical evidence for various immunotherapies and multiple clinical trials. This work reviews the history and advances in active immunotherapy, checkpoint blockade, and adoptive T-cell therapy for pediatric brain tumors, including ongoing clinical trials.

Original language	English (US)
Pages (from-to)	1226-1238
Number of pages	13
Journal	Neuro-oncology
Volume	21
Issue number	10
DOIs	https://doi.org/10.1093/neuonc/noz077
State	Published - Oct 9 2019

Keywords

Brain tumor
Immunotherapy
Pediatric

ASJC Scopus subject areas

Clinical Neurology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/neuonc/noz077

Cite this

@article{c0edf075ded54a3899af0b79eac1bfb9,

title = "Immunotherapy for pediatric brain tumors: Past and present",

abstract = "The field of cancer immunotherapy has progressed at an accelerated rate over the past decade. Pediatric brain tumors thus far have presented a formidable challenge for immunotherapy development, given their typically low mutational burden, location behind the blood-brain barrier in a unique tumor microenvironment, and intratumoral heterogeneity. Despite these challenges, recent developments in the field have resulted in exciting preclinical evidence for various immunotherapies and multiple clinical trials. This work reviews the history and advances in active immunotherapy, checkpoint blockade, and adoptive T-cell therapy for pediatric brain tumors, including ongoing clinical trials.",

keywords = "Brain tumor, Immunotherapy, Pediatric",

author = "Foster, {Jessica B.} and Madsen, {Peter J.} and Meenakshi Hegde and Nabil Ahmed and Cole, {Kristina A.} and Maris, {John M.} and Resnick, {Adam C.} and Storm, {Phillip B.} and Waanders, {Angela J.}",

note = "Funding Information: This work is supported by the Children{\textquoteright}s Brain Tumor Tissue Consortium (CBTTC), and we are grateful to all of the donors/ foundations that have provided financial support to CBTTC. Research also supported by St. Baldrick{\textquoteright}s-Stand Up to Cancer Dream Team Translational Research Grant (SU2C-AACR-DT-27-17). Stand Up to Cancer is a division of the Entertainment Industry Foundation. Research Grants are administered by the American Association for Cancer Research, the Scientific Partner of SU2C. Publisher Copyright: {\textcopyright} The Author(s) 2019.",

year = "2019",

month = oct,

day = "9",

doi = "10.1093/neuonc/noz077",

language = "English (US)",

volume = "21",

pages = "1226--1238",

journal = "Neuro-oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Immunotherapy for pediatric brain tumors

T2 - Past and present

AU - Foster, Jessica B.

AU - Madsen, Peter J.

AU - Hegde, Meenakshi

AU - Ahmed, Nabil

AU - Cole, Kristina A.

AU - Maris, John M.

AU - Resnick, Adam C.

AU - Storm, Phillip B.

AU - Waanders, Angela J.

N1 - Funding Information: This work is supported by the Children’s Brain Tumor Tissue Consortium (CBTTC), and we are grateful to all of the donors/ foundations that have provided financial support to CBTTC. Research also supported by St. Baldrick’s-Stand Up to Cancer Dream Team Translational Research Grant (SU2C-AACR-DT-27-17). Stand Up to Cancer is a division of the Entertainment Industry Foundation. Research Grants are administered by the American Association for Cancer Research, the Scientific Partner of SU2C. Publisher Copyright: © The Author(s) 2019.

PY - 2019/10/9

Y1 - 2019/10/9

N2 - The field of cancer immunotherapy has progressed at an accelerated rate over the past decade. Pediatric brain tumors thus far have presented a formidable challenge for immunotherapy development, given their typically low mutational burden, location behind the blood-brain barrier in a unique tumor microenvironment, and intratumoral heterogeneity. Despite these challenges, recent developments in the field have resulted in exciting preclinical evidence for various immunotherapies and multiple clinical trials. This work reviews the history and advances in active immunotherapy, checkpoint blockade, and adoptive T-cell therapy for pediatric brain tumors, including ongoing clinical trials.

AB - The field of cancer immunotherapy has progressed at an accelerated rate over the past decade. Pediatric brain tumors thus far have presented a formidable challenge for immunotherapy development, given their typically low mutational burden, location behind the blood-brain barrier in a unique tumor microenvironment, and intratumoral heterogeneity. Despite these challenges, recent developments in the field have resulted in exciting preclinical evidence for various immunotherapies and multiple clinical trials. This work reviews the history and advances in active immunotherapy, checkpoint blockade, and adoptive T-cell therapy for pediatric brain tumors, including ongoing clinical trials.

KW - Brain tumor

KW - Immunotherapy

KW - Pediatric

UR - http://www.scopus.com/inward/record.url?scp=85073085252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073085252&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noz077

DO - 10.1093/neuonc/noz077

M3 - Article

C2 - 31504801

AN - SCOPUS:85073085252

SN - 1522-8517

VL - 21

SP - 1226

EP - 1238

JO - Neuro-oncology

JF - Neuro-oncology

IS - 10

ER -

Immunotherapy for pediatric brain tumors: Past and present

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this